- Home
- KYTX
as 11-08-2024 4:00pm EST
Stocks
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 242.1M | IPO Year: | 2024 |
| Target Price: | $23.25 | AVG Volume (30 days): | 262.9K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.40 - $30.60 | Next Earning Date: | 11-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest KYVERNA THERAPEUTICS INC News
KYTX Breaking Stock News: Dive into KYTX Ticker-Specific Updates for Smart Investing
PR Newswire
18 days ago
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Insider Monkey
20 days ago
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy
GuruFocus.com
a month ago
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc
MT Newswires
a month ago
UBS Initiates Kyverna Therapeutics at Buy With $13 Price Target
PR Newswire
2 months ago
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
MT Newswires
2 months ago
Kyverna Therapeutics Names Warner Biddle CEO
PR Newswire
2 months ago
Kyverna Therapeutics Announces Leadership Update
BioPharma Dive
2 months ago
Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’
Compare KYTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KYTX KYVERNA THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.